drugset / Trial / NCT05467553
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
Timeline
- Start
- 2023-02-24
- Primary completion
- 2025-02-28
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 450 ug | Subcutaneous |
| Subject | Ursodeoxycholic Acid | Small molecule | 15 mg/kg | — |
| Background | tenofovir alafenamide | Small molecule | 25 mg | Oral |